HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including ...

Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: SES AI Corp (SES) 31.66% +3.02, Faraday ...

Aubrey Crispen, Athens: She hammered two home runs and drove in five as Athens topped Petersburg PORTA 11-6 in a Sangamo ...

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia B, making it the first approved gene therapy for the disorder in the ...

And then of course, we’ll also be monitoring functional measures like muscle strength and stride velocity.’ Sangamo Therapeutics, headquartered in Richmond, US, is another company aiming to solve the ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: NEWSMAX INC (NMAX) 212.99% +7.55, Canadian Solar (CSIQ) 5.23% +2.11, Sangamo (SGMO) 2.62% +1.10 ...

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for central nervous system (CNS) diseases. The deal gives Lilly an exclusive ...

SEONGNAM, South Korea I April 7, 2025 I ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, ...